Compounds > fenofibrate

fenofibrate and transforming growth factor beta

fenofibrate has been researched along with transforming growth factor beta in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (45.45)29.6817
2010's6 (54.55)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aizawa, Y; Fuse, K; Hirono, S; Kato, K; Kodama, M; Maruyama, S; Miida, T; Nakagawa, O; Nakazawa, M; Watanabe, K; Yamamoto, T1
Amiri, F; Benkirane, K; Cohn, JS; Diep, QN; Endemann, D; Schiffrin, EL1
Ballinger, ML; Dilley, RJ; Jennings, GL; Little, PJ; Nigro, J; Wight, TN1
Bode, C; Ernst, S; Leugers, A; Nordt, TK; Sobel, BE; Willecke, F; Zirlik, A1
Chanda, D; Chiang, JY; Choi, HS; Hwang, JH; Jeong, KH; Kim, DK; Kim, YH; Kweon, GR; Lee, CH; Lee, IK; Lee, MR; Noh, JR; Oh, GT; Park, JH; Shong, M1
Bu, P; Hou, X; Li, C; Shen, YH; Wang, F; Zhang, C; Zhang, Y1
Banfi, C; Brioschi, M; Castiglioni, L; Cimino, M; Gelosa, P; Gianella, A; Nobili, E; Pignieri, A; Sironi, L; Tremoli, E1
Amann, T; Bauer, S; Buechler, C; Eisinger, K; Hellerbrand, C; Neumeier, M; Schäffler, A; Schölmerich, J; Walter, R; Wanninger, J; Weiss, TS1
Chew, GT; Glineur, C; Gross, B; Lamas, S; Martin-Nizard, F; Neve, B; Rodríguez-Pascual, F; Rommens, C; Staels, B; Watts, GF1
Chen, L; Cheng, L; Chi, W; Deng, H; Feng, Y; Ge, M; Hu, X; Huang, Y; Huo, Y; Kuang, W; Lan, Z; Li, L; Liu, X; Liu, Y; Luo, M; Ma, Z; Siegenthaler, JA; Sun, K; Xi, Q; Xu, L; Yang, J; Zhang, B; Zhang, Y; Zhao, X1
Czyż, J; Kądziołka, D; Lasota, S; Madeja, Z; Michalik, M; Paw, M; Sęk, A; Wnuk, D1

Trials

1 trial(s) available for fenofibrate and transforming growth factor beta

ArticleYear
Fenofibrate inhibits endothelin-1 expression by peroxisome proliferator-activated receptor α-dependent and independent mechanisms in human endothelial cells.
    Arteriosclerosis, thrombosis, and vascular biology, 2013, Volume: 33, Issue:3

    Topics: Apoptosis Regulatory Proteins; Binding Sites; Brachial Artery; Cell Cycle Proteins; Cell Line; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Down-Regulation; Dyslipidemias; Endothelial Cells; Endothelin-1; Fenofibrate; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Hypolipidemic Agents; Phosphorylation; PPAR alpha; Promoter Regions, Genetic; Repressor Proteins; Signal Transduction; Time Factors; Transcription, Genetic; Transfection; Transforming Growth Factor beta; Vasodilation

2013

Other Studies

10 other study(ies) available for fenofibrate and transforming growth factor beta

ArticleYear
Fenofibrate, a peroxisome proliferator-activated receptor alpha activator, suppresses experimental autoimmune myocarditis by stimulating the interleukin-10 pathway in rats.
    Journal of atherosclerosis and thrombosis, 2002, Volume: 9, Issue:2

    Topics: Animals; Autoimmune Diseases; Disease Models, Animal; Fatty Acids; Fenofibrate; Gene Expression; Hypolipidemic Agents; Interleukin-1; Interleukin-10; Male; Myocarditis; Myocardium; Rats; Rats, Inbred Lew; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha

2002
PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats.
    Journal of molecular and cellular cardiology, 2004, Volume: 36, Issue:2

    Topics: Angiotensin II; Animals; Blood Pressure; Collagen; Electrocardiography; Fenofibrate; Fibrosis; Heart; Hypertension; Inflammation; Infusions, Intravenous; Intercellular Adhesion Molecule-1; Myocardium; NF-kappa B; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1

2004
Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces lipoprotein binding.
    Diabetologia, 2004, Volume: 47, Issue:12

    Topics: Cells, Cultured; Fenofibrate; Glycosaminoglycans; Humans; Hypolipidemic Agents; Insulin; Lipoproteins; Mammary Arteries; Muscle, Smooth, Vascular; Platelet-Derived Growth Factor; Proteoglycans; Transforming Growth Factor beta

2004
Inhibition by fibrates of plasminogen activator inhibitor type-1 expression in human adipocytes and preadipocytes.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:6

    Topics: Adipocytes; Adipose Tissue; Adult; Aged; Animals; Cells, Cultured; Female; Fenofibrate; Gemfibrozil; Gene Expression Regulation; Humans; Hypolipidemic Agents; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Plasminogen Activator Inhibitor 1; PPAR alpha; Stem Cells; Transforming Growth Factor beta

2009
Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytokines; Fenofibrate; Male; Mice; Mice, Inbred C57BL; Plasminogen Activator Inhibitor 1; PPAR alpha; Pyrimidines; Rats; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Transcription Factors; Transforming Growth Factor beta

2009
PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity.
    Biochemical and biophysical research communications, 2010, Apr-09, Volume: 394, Issue:3

    Topics: Animals; Antioxidants; Collagen; Fenofibrate; Hypertension; Kidney Diseases; Male; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; PPAR alpha; Rats; Rats, Inbred SHR; Superoxide Dismutase; Transforming Growth Factor beta

2010
Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats.
    The Journal of pharmacology and experimental therapeutics, 2010, Volume: 335, Issue:2

    Topics: Animals; Blotting, Western; Brain; Chemokine CCL2; Clofibrate; Disease Models, Animal; Fenofibrate; Hypertension; Inflammation; Interleukin-1beta; Kidney Diseases; Ligands; Male; Oxidative Stress; PPAR alpha; Rats; Rats, Inbred SHR; Stroke; Transforming Growth Factor beta

2010
Adiponectin reduces connective tissue growth factor in human hepatocytes which is already induced in non-fibrotic non-alcoholic steatohepatitis.
    Experimental and molecular pathology, 2011, Volume: 91, Issue:3

    Topics: Adiponectin; Anticholesteremic Agents; Connective Tissue Growth Factor; Down-Regulation; Fatty Liver; Female; Fenofibrate; Hepatocytes; Humans; Male; Non-alcoholic Fatty Liver Disease; Phosphorylation; PPAR alpha; Primary Cell Culture; Pyrimidines; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta

2011
Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity.
    Archives of toxicology, 2018, Volume: 92, Issue:1

    Topics: Animals; Benzamides; Cell Line; Coenzyme A Ligases; Dioxoles; Epithelial Cells; Fatty Acids; Fenofibrate; Fibrosis; Humans; Kidney Diseases; Kidney Tubules; Lipid Metabolism; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Oxidation-Reduction; Transforming Growth Factor beta; Zoledronic Acid

2018
Fenofibrate Reduces the Asthma-Related Fibroblast-To-Myofibroblast Transition by TGF-Β/Smad2/3 Signaling Attenuation and Connexin 43-Dependent Phenotype Destabilization.
    International journal of molecular sciences, 2018, Aug-29, Volume: 19, Issue:9

    Topics: Asthma; Cell Proliferation; Cell Survival; Cells, Cultured; Connexin 43; Fenofibrate; Fibroblasts; Humans; Myofibroblasts; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta

2018